HLA-B*57 as a Dominant Genetic Determinant of HIV-1 Elite Control: Comparative Reanalysis of MHC Variant Associations in European andAfrican-American Cohorts A reanalysis of published genomic association data

Most people who contract HIV-1, the virus that causes AIDS, will see their immune system struggle to keep the infection in check without medication. Over time, the virus multiplies, and the disease progresses. However, a tiny fraction of infected individuals, known as elite controllers, are different. These people, making up less than half a percent of those with the virus, maintain undetectable levels of HIV in their blood without ever taking antiretroviral drugs. Their bodies naturally suppress the infection. Scientists have long known that a specific region of human DNA, which acts as the immune system's instruction manual for recognizing invaders, holds the key to this rare ability. Within this region, a particular genetic variant called HLA-B57 has been identified as the most powerful known factor helping people of European descent become elite controllers. In populations with African ancestry, where a slightly different version of this gene, HLA-B57:03, is more common, researchers suspected a similar protective role, but the details of how these genes work across different groups remained less clear.

A new reanalysis of existing data brings these two genetic stories together to see how they compare. The study, led by Emmanuel Owusu Frimpong, did not collect new blood samples or run new genetic tests. Instead, it took published numbers from two large, previously completed studies and examined them with fresh eyes to understand the strength and nature of the genetic protection. The researchers focused on a European group containing 543 elite controllers and over 3,000 uninfected people, and an African-American group of nearly 760 people living with HIV, many of whom were elite controllers. The goal was to confirm how strongly the protective gene works, whether its effect changes as the amount of virus in the blood changes, and if other nearby genetic signals act independently or only when the main protective gene is present.

In the European group, the connection between the HLA-B*57 gene and elite control was strikingly strong. The researchers found that nearly 30 percent of the elite controllers carried this gene, compared to only about 6.5 percent of the uninfected control group. This difference was not a small fluctuation; it was a massive statistical signal indicating that carrying this gene makes a person nearly six times more likely to be an elite controller. Beyond just presence or absence, the study looked at how the gene related to the amount of virus in the blood. The researchers divided the infected individuals into three groups based on their viral load: low, medium, and high. They discovered a clear, graded pattern: the gene was most common in the group with the lowest virus levels and least common in the group with the highest. This suggests the gene does not just act as a simple on-off switch but helps to push the virus down to lower levels in a dose-dependent way.

The analysis also peeled back the layers of the genetic region to see what else was happening. The European dataset included information on nine different genetic markers in this immune region. When the researchers looked at people who did not have the main protective HLA-B57 gene, they found that eight other markers still showed a significant link to elite control. This means there are other genetic factors at play that can help control the virus even without the primary shield. However, when they looked at the people who did have the HLA-B57 gene, only one of those other markers remained significant. This implies that once the main protective gene is present, it dominates the picture, and the other signals become less visible or perhaps less necessary for that specific individual's control.

The picture for the African-American cohort was supportive but structurally different. Because the original data for this group did not break down the genetic carriers by elite controller status versus other infected individuals, the researchers could not perform the same direct comparison as they did for the Europeans. Instead, they compared the frequency of the African-specific protective gene variant, HLA-B*57:03, in the study group against the general African population. They found that the gene variant was significantly more common in the study group, which was enriched with elite controllers, appearing in about 9 percent of the study participants compared to 3.7 percent in the general population. This enrichment confirms that the gene is likely protective in this population as well, but the study design prevents a direct calculation of how much more likely a carrier is to be an elite controller compared to the European findings. The researchers noted that the numbers cannot be directly compared between the two groups because the African-American analysis measured a different contrast: the gene's presence in a group of infected people versus the general public, rather than a direct match between elite controllers and uninfected people.

The study concludes that the HLA-B*57 family of genes is a dominant force in HIV control across different ancestries, though the specific version of the gene differs between populations. For people of European descent, the evidence is direct and detailed, showing a strong, graded relationship with viral suppression and revealing a complex landscape of other supporting genetic signals. For people of African descent, the evidence strongly supports the same protective role for the related gene variant, but the full depth of the relationship remains to be fully mapped. The researchers emphasize that future work should aim to gather the same level of detailed data for African-ancestry populations, ensuring that the genetic story of HIV control is told with equal clarity for all people, regardless of their background.